Stocks Health care BCDA
NASDAQ · Health careBioCardia, Inc. (BCDA)
It posted a net loss of $7.3M. In fiscal 2025 capital spending exceeded operating cash flow by $7.4M. At June 30, 2026 it held $4.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about BioCardia, Inc.
- Net worth
- BioCardia, Inc. has a market value (market cap) of $14.1M at the latest share price, and shareholders' equity of $2.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $8.2M.
- Cash flow
- In fiscal 2025 operations used $7.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- BioCardia, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What BioCardia, Inc. does
BioCardia, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCDA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$8.2M | -$1.23 | -$7.4M |
| 2024 | $58K | -$7.9M | -$2.90 | -$7.9M |
| 2023 | $477K | -$11.6M | -$8.19 | -$10M |
| 2022 | $1.4M | -$11.9M | -$9.98 | -$10.6M |
| 2021 | $1M | -$12.6M | -$11.17 | -$10.5M |
| 2020 | $145K | -$15M | -$22.04 | -$12.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What BioCardia, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Other event 8-K
- September 23, 2026Other event 8-K
- September 21, 2026Other event 8-K
- September 10, 2026Other event 8-K
- August 24, 2026
- August 21, 2026
- August 12, 2026
- August 12, 2026
- June 18, 2026
- June 12, 2026
Insider trades
What the people running BioCardia, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $8.9K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Altman PeterPresident and CEO, Director | Bought | 1,000 | $1K |
| September 23, 2026 | Altman PeterPresident and CEO, Director | Bought | 1,900 | $2K |
| September 3, 2026 | Altman PeterPresident and CEO, Director | Bought | 800 | $872 |
| August 17, 2026 | Altman PeterPresident and CEO, Director | Bought | 5,400 | $5K |
| August 13, 2026 | Altman PeterPresident and CEO, Director | Bought | 1,900 | $1.7K |
| July 29, 2026 | Altman PeterPresident and CEO, Director | Bought | 5,000 | $3.9K |
| July 17, 2026 | Altman PeterPresident and CEO, Director | Bought | 500 | $415 |
| July 15, 2026 | Altman PeterPresident and CEO, Director | Bought | 1,500 | $1.3K |
Who owns BCDA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Thomas A. Satterfield, Jr.13G, passive | 9.9% | August 13, 2025 |
| Lincoln Alternative Strategies LLC13G, passive | 7.54% | September 19, 2025 |
| Blank Andrew Scott13D, may seek influence | 5.5% | May 22, 2025 |
Largest institutional holders
Insiders
4 insiders reported holding 719,594 shares in total, about $669.4K at the last price.
| Holder | Shares |
|---|---|
| Altman PeterPresident and CEO, Director | 384,885 |
| Stertzer Simon HDirector | 166,338 |
| McClung DavidChief Financial Officer | 114,245 |
| Gillis Edward MSenior Vice President, Devices | 54,126 |
Questions about BCDA
What does BioCardia, Inc. do?
BioCardia, Inc. is a company in the Health care sector, listed on NASDAQ as BCDA. Its shares trade on NASDAQ under the ticker BCDA.
What is BioCardia, Inc.'s net worth?
BioCardia, Inc. has a market value (market cap) of $14.1M at the latest share price, and shareholders' equity of $2.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BioCardia, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $7.3M.
When did BioCardia, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 1, 2026.
When is BioCardia, Inc.'s next earnings report?
BioCardia, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare BCDA with
Follow BCDA
Get an email when BioCardia, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BioCardia, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.